The firm also said this week that the NCCN added the HER2xHER3 bispecific antibody to its biliary tract cancer treatment guidelines.

While bota-vec failed to meet a Phase III primary endpoint, MeiraGTx remains committed to bringing the gene therapy to patients with X-linked retinitis pigmentosa.

The firm will launch a new pivotal trial after the EMA's CHMP last year recommended against conditional marketing authorization for the gene therapy.

The firm will use the funds to advance its KIR-CAR platform, which adapts dual receptors from NK cells to allow CAR T cells to rest when not actively targeting tumors.

The firm will deliver SGT-212 to patients' brains and intravenously to try to restore frataxin levels and diminish ...

The firms plan to integrate and standardize datasets and registries from patient-led groups and identify cohorts for use in clinical trials.

PrecisionLife and Ovation.io on Wednesday said they inked an agreement to launch a consumer-facing genetic test for identifying patients' likelihood of responding to GLP-1 receptor agonists. The ...

The firm is now expecting double the gross proceeds from its previously announced common stock and conversable senior note offerings.

The funds will help the combined firm, which will operate as Obsidian and apply to trade on the Nasdaq, advance an investigational TIL therapy for melanoma and lung cancer.

The company is hoping to seek accelerated approval in first-line HLA-A*A2:01-negative metastatic uveal melanoma based on data ...

In the ARROW trial, researchers found that different RET fusion partners affected the durability of patients' responses, a finding that could be useful for guiding treatment.

Researchers believe the therapy, which targets CD83, can selectively target leukemia cells and treat side effects of stem cell transplants.